tazemetostat
Showing 1 - 25 of 36
Relapsed/Refractory Follicular Lymphoma With EZH2 Trial in Shanghai (Tazemetostat)
Not yet recruiting
- Relapsed/Refractory Follicular Lymphoma With EZH2
- Tazemetostat
-
Shanghai, Shanghai, ChinaShanghai Cancer Center
Jul 20, 2022
Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma Trial in Boston (TAZEMETOSTAT, Zandelisib)
Not yet recruiting
- Relapsed Follicular Lymphoma
- Refractory Follicular Lymphoma
- TAZEMETOSTAT
- Zandelisib
-
Boston, Massachusetts
- +1 more
Oct 28, 2022
Relapsed/Refractory Lymphoma Trial in Shanghai (tazemetostat, HMPL-689)
Not yet recruiting
- Relapsed/Refractory Lymphoma
- tazemetostat
- HMPL-689
-
Shanghai, ChinaRuijin Hospital, Shanghai Jiaotong University School of Medicine
Feb 2, 2023
Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial in New York (Venetoclax, Tazemetostat)
Not yet recruiting
- Lymphoma, Non-Hodgkin
- +2 more
- Venetoclax
- Tazemetostat
-
New York, New YorkWeill Cornell Medicine/NewYork-Presberteryian Hospital
Jan 18, 2023
Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer Trial in Boston (Talazoparib, Tazemetostat)
Recruiting
- Metastatic Prostate Cancer
- Metastatic Castration-resistant Prostate Cancer
- Talazoparib
- Tazemetostat
-
Boston, Massachusetts
- +1 more
Jul 18, 2022
Peripheral Nerve Sheath Tumor Trial in Gainesville (Tazemetostat)
Recruiting
- Peripheral Nerve Sheath Tumor
- Tazemetostat
-
Gainesville, FloridaUniversity of Florida
Feb 7, 2022
Solid Tumor, ARID1A Gene Mutation Trial in Greenville (Tazemetostat)
Recruiting
- Solid Tumor
- ARID1A Gene Mutation
- Tazemetostat
-
Greenville, South CarolinaPrisma Health Cancer Institute
Feb 15, 2022
COVID-19 Acute Respiratory Distress Syndrome, Cytokine Release Syndrome Trial (Tazemetostat)
Withdrawn
- COVID-19 Acute Respiratory Distress Syndrome
- Cytokine Release Syndrome
- Tazemetostat
- (no location specified)
Nov 17, 2021
Recurrent DLBCL Germinal Center B-Cell Type, Recurrent Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma Trial (Belinostat,
Not yet recruiting
- Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
- +5 more
- Belinostat
- +2 more
- (no location specified)
Dec 2, 2022
Head and Neck Squamous Cell Carcinoma Trial in Saint Louis (Tazemetostat, Pembrolizumab)
Recruiting
- Head and Neck Squamous Cell Carcinoma
- Tazemetostat
- Pembrolizumab
-
Saint Louis, MissouriWashington University School of Medicine
May 26, 2022
Non Small Cell Lung Cancer Trial in West Los Angeles (Tazemetostat)
Not yet recruiting
- Non Small Cell Lung Cancer
- Tazemetostat
-
West Los Angeles, CaliforniaVA Greater Los Angeles Healthcare System, West Los Angeles, CA
Jul 21, 2022
Relapsed/Refractory Trial in Santa Fe (Tafasitamab, Lenalidomide, Tazemetostat)
Recruiting
- Relapsed/Refractory
- Tafasitamab
- +8 more
-
Santa Fe, CaliforniaCalifornia Cancer Associates For Research And Excellence, cCARE
Feb 23, 2022
Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma Trial in Duarte (Tazemetostat, Ublituximab, Umbralisib)
Not yet recruiting
- Recurrent Follicular Lymphoma
- Refractory Follicular Lymphoma
- Tazemetostat
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jul 31, 2022
Atypical Teratoid Rhabdoid Tumor, INI1 (SMARCB1)-Deficient Primary CNS Malignant Tumors, SMARCA4-deficient Primary CNS Malignant
Not yet recruiting
- Atypical Teratoid Rhabdoid Tumor
- +6 more
- Tazemetostat
- +2 more
-
Boston, Massachusetts
- +1 more
Jun 2, 2022
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma Trial in Isehara, Chuo-ku (tazemetostat)
Completed
- Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
- tazemetostat
-
Isehara, Kanagawa, Japan
- +1 more
Aug 20, 2021
Epithelioid Sarcoma (Ex-US Only), Spindle Cell Sarcoma, Sinonasal Carcinoma Trial (Tazemetostat)
Available
- Epithelioid Sarcoma (Ex-US Only)
- +5 more
- Tazemetostat
- (no location specified)
Aug 16, 2021
Diffuse Large B Cell Lymphoma, Primary Mediastinal Lymphoma, Mantle Cell Lymphoma Trial in Tucson, Tampa, New York
Completed
- Diffuse Large B Cell Lymphoma
- +4 more
- Tazemetostat
- +3 more
-
Tucson, Arizona
- +2 more
Mar 23, 2021
B-cell Lymphomas (Phase 1), Advanced Solid Tumors (Phase 1), Diffuse Large B-cell Lymphoma (Phase 2) Trial in Worldwide
Completed
- B-cell Lymphomas (Phase 1)
- +5 more
- Tazemetostat
-
Birmingham, Alabama
- +51 more
Dec 8, 2021
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Philadelphia (Palbociclib, Tazemetostat,
Not yet recruiting
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Palbociclib
- +4 more
-
Philadelphia, PennsylvaniaThomas Jefferson University Hospital
Jan 13, 2023
Follicular Lymphoma, Non Hodgkin Lymphoma, Lymphoma Trial in Edmonds, Issaquah, Seattle (Tazemetostat, Rituximab)
Terminated
- Follicular Lymphoma
- +2 more
- Tazemetostat
- Rituximab
-
Edmonds, Washington
- +2 more
Mar 1, 2021
Relapsed or Refractory Follicular Lymphoma With Enhancer of
Recruiting
- Lymphoma, Follicular
- Tazemetostat
-
Fukuoka-shi, Fukuoka, Japan
- +20 more
Jan 27, 2022
Follicular Lymphoma Trial in United States (Tazemetostat, Rituximab)
Recruiting
- Follicular Lymphoma
- Tazemetostat
- Rituximab
-
Birmingham, Alabama
- +19 more
Mar 29, 2022
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma Trial in Japan (Tazemetostat)
Completed
- Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
- Tazemetostat
-
Nagoya, Aichi, Japan
- +27 more
Jan 13, 2022